ARTES Biotechnology GmbH
Company Profile

ARTES Biotechnology
Efficient technologies for cost-sensitive production of recombinant proteins
ARTES Biotechnology GmbH is a profitable German contract research and development company providing innovative solutions in recombinant protein production to pharmaceutical companies. The focus of the service and license offer is on gene expression in the high-yield yeast expression systems Hansenula polymorpha (methylotrophic alternative to Pichia). This platform technology of ARTES is secured by own IP and by exclusive licenses. ARTES´ experienced staff and an international network of strategic collaboration partners provide customised service packages covering the areas gene analysis and design, production strain generation and characterization, protein analysis, fermentation development and downstream processing, as well as process upscale and cGMP production. ARTES´ high standards in contract research and project documentation form the basis for fast product commercialisation, best demonstrated by successful FDA approvals and European clinical studies of clients´ proteins, ranging from enzymes to therapeutic products. Several processes for bio-similar API production are available from ARTES resulting in low-cost manufacturing of high-value products. With its expertise in technology transfer and set-up of manufacturing processes ARTES is the ideal partner to guarantee fast and secure technology transfer to local production sites.

Feasibility Studies ARTES Biotechnology offers tailor-made feasibility studies for the generation of recombinant Hansenula production cell lines to provide the most efficient solution for your protein manufacturing. A team with up to 20 years experience in contract research and in trouble-shooting of expression problems focuses on your individual project. A proven track record in this area of yeast research and the broad platform of tools and technologies available from ARTES Biotechnology